Sparing R, Sellhaus B, Noth J, Block F
Neurologische Klinik, Universitätsklinikum der RWTH Aachen.
Nervenarzt. 2003 Feb;74(2):167-71. doi: 10.1007/s00115-002-1441-x.
Cerivastatine was administered as a reversible HMG-CoA reductase inhibitor (statine) to treat hypercholesterolemia until its withdrawal from the market following 52 reports of death due to drug-related rhabdomyolysis and acute renal failure. In most cases, cerivastatine was applied in combination with drugs which influenced the liver metabolism of cerivastatine via cytochromeoxidase P 450 isoenzymes. We report a well-documented case of acute rhabdomyolysis following cerivastatine monotherapy. The diagnosis was confirmed additionally by muscle biopsy.Finally,we give an overview of the current knowledge concerning therapy with HMG-CoA reductase inhibitors,1 year after the withdrawal of cerivastatine from the market.
西立伐他汀作为一种可逆性HMG-CoA还原酶抑制剂（他汀类）用于治疗高胆固醇血症，直至因52例与药物相关的横纹肌溶解症和急性肾衰竭死亡报告而退出市场。在大多数情况下，西立伐他汀与通过细胞色素氧化酶P 450同工酶影响其肝脏代谢的药物联合使用。我们报告了一例记录完整的西立伐他汀单药治疗后急性横纹肌溶解症的病例。肌肉活检进一步证实了诊断。最后，在西立伐他汀退出市场1年后，我们概述了目前关于HMG-CoA还原酶抑制剂治疗的知识。
